World Journal of Pharmaceutical and Life Sciences
WJPLS
www.wjpls.org
SJIF Impact Factor: 7.409

A REVIEW ON PERSONALIZED MEDICINE IN CANCER TREATMENT BASED ON GENETIC PROFILING

Shubamalya L. G.[1*], S. B. Nirmita[2], Uttarker Kalyan[3], Melba A.[4], Krishna K. S.[5] and Lakshana K.[6]

[1]Pharm.D, Rao's College of Pharmacy, Nellore. drshubamalyapharmd@gmail.com
[2]Pharm.D, PSG College of Pharmacy, Coimbatore. nirmitasamivel@gmail.com
[3]Pharm.D, Rao's College of Pharmacy, Nellore. uttarkerkalyan18@gmail.com
[4]Pharm.D, RVS College of Pharmaceutical Science, Coimbatore. melbaambrose9@gmail.com
[5]MSc Biotechnology, College Sri Ramakrishna College of Arts & Science, Coimbatore. krishnakambrath123@gmail.com
[6]Bio-Medical Engineering, Sri Shakthi Institute of Engineering and Technology, Coimbatore. laksshh29@gmail.com

***Corresponding Author: Shubamalya L. G.**
Pharm. D, Rao's College of Pharmacy, Nellore.
Email ID: drshubamalyapharmd@gmail.com

Article Received on 18/12/2024 **Article Revised on 08/01/2025** **Article Accepted on 29/01/2025**

ABSTRACT
With the individualization of treatment through patterns of genetic profiling, personalized medicine is altering cancer treatment enabling the creation of individualized therapies as per what has been detected to be unique concerning the patient in terms of genetics. Genetic profiling provides evidence for certain mutations, for losses or amplifications of genes, and for particular molecular markers in the tumor, and selects the most appropriate therapies. NGS, liquid biopsy, and bioinformatics are the innovations most embedded into the practice, as they also provide deeper understanding into tumor biology and how such tumors respond to treatment. The role of genetic profiling in personalized cancer therapy is weighed up in this review, addressing how it may be applied to target selection for therapies, immunotherapies, and chemotherapy regimens. Also discussed are the benefits on the clinical side, including increased rates of survival, fewer side effects, and improved quality of life for patients. However, some limitations to widespread use exist: expensive genetic testing, limited treatment access, and the inherent complexity with which genetic data are interpreted. The future of personalized medicine in cancer lies in multi-omics technologies, artificial intelligence, and improving accessibility because these elements combined can further revolutionize cancer care and emphasizes outcomes.

KEYWORDS: Personalized medicine, cancer therapy, genetic profiling, next-generation sequencing.

INTRODUCTION
Cancer is one such disease, which causes death in most parts of the world. It is a group of diseases caused by uncontrolled division and multiplication of abnormal cells. Major advances in conventional cancer therapy such as surgery, chemotherapy, and radiation therapy have increased the survival of patients, but there are also drawbacks in these therapies. For example, the ones who will receive the treatment will be of different groups, and they will respond to the particular treatment differently. Such treatments happen to cause side effects, which could result in a lowered quality of life for the patient. In recent times, there has been more of a need for therapies that are very specific and targeted to overcome these issues.[1,2]

Personalized medicine or precision medicine is a novel intervention in cancer treatment that customizes interventions on an individual basis according to genetic or molecular and environmental factors. Regarding the individual understanding of patients' cancer genetic profiles, clinicians would select the least toxic and the most efficient treatment for that particular individual. By the introduction of molecular diagnostics through genetic profiling, personalized medicine is going to match patients to those medicines specifically designed to target their individual structural alterations and pathways that drive their cancers.

Therefore, genetic profiling has a key role to play in personalized oncology, whereby the specific mutations, expressions of genes, and molecular alterations in cancer cells are identified. All this would help oncologists to find treatments that would probably work well with that patient case. Genetic profiling allows detection of biomarkers associated with certain cancer subtypes;

hence, targeted therapies can be developed, focusing their action solely on the cancer cells while leaving healthy tissue unaffected. Such an approach also predicts how certain patients will respond to particular drugs, thus reducing adverse effects and leading to a better overall outcome.[3,4]

PERSONALIZED MEDICINE IN ONCOLOGY

Personalised medicine, otherwise known as precision medicine, would be the approach of health care, which is tending to treatment approaches according to the person's profile including genetic, molecular and environmental aspects. This, in oncology, means that physicians will look at the genetic and molecular profiles of the cancer and the patients so that they can choose from the available treatment modalities those that provide maximum effect with relatively lower side effects. Personalized medicine inherited this thought from the various advances in genetic and molecular sciences, which turned genomics and proteomics into sources of revelation about very wide-range of molecular heterogeneities in cancers. Realization that such a treatment is ineffective in addressing the complexities of cancer led to the emergence of personalized medicine-the application of an individual's tumor's molecular features in the design of appropriate targeted therapies.[5,6]

EVOLUTION OF PERSONALIZED ONCOLOGY

The development of personalized oncology has progressed through major advances in our understanding of cancer biology, as well as in the technologies for precise individualized therapeutic approaches. Many important genetic research, molecular diagnostics, and therapeutic milestones contributed to these transformations occurring in succession.

1. Early Understanding of Cancer (Pre-1990s)

Historically, cancer treatment was generic; chemotherapy, radiation therapy, and surgery were the main forms of treatment. These treatments were meant to eliminate cancer cells but were not specific to individual patient tumor characteristics. They were side effects and general damage because they worked on both normal and tumor cells. At that time, there was very little understanding of the genetic and molecular behavior of various cancers.

- **Chemotherapy**: Chemotherapy made possible the active destruction of any rapidly dividing cell, including tumor cells, yet it was not restricted to them. Hence there was extensive toxic damage to the other normal tissues.
- **Radiation Therapy**: Radiation therapy was also directed toward destruction of cancer cells but besides that, surrounding tissues received its share of injury, causing a multitude of side effects.[7,8]

2. Molecular Biology Revolution (1990s–2000s)

The advances in molecular biology brought about revolution in the very late 20th century. The discovery of the genetic basis of cancer opened the doors for further directed therapeutics.

- **Human Genome Project**: The hallmark of the Human Genome Project completion in 2003 was the scheming of a map of all human genes. This monumental achievement has made it possible for researchers to identify the genetic mutations and variations now believed to drive cancer.

- **Identification of Oncogenes and Tumor Suppressor Genes**: Specific genes that turned out to be associated with cancer progression were identified during this period, such as oncogenes (e.g. HER2, EGFR) and tumor suppressor genes (e.g. p53, BRCA1, BRCA2). That understanding has led to targeted therapeutics being developed to address the specific alterations in these genes.

In a parallel, the idea of molecular profiling the tumors started shaping, where specific cancer cells or tissues could be analyzed for specific mutations, patterns of gene expression, and protein markers.[9,10]

3. Emergence of Targeted Therapies (2000s–Present)

New era of targeted therapies has come with the advancement of molecular diagnostics. Targeted therapies are therapies that have been designed to specifically target the genetic mutations or proteins driving the cancer as opposed to killing both cancerous and healthy cells indiscriminately like the earlier forms of treatment.

- **EGFR Inhibitors in Non-Small Cell Lung Cancer**: EGFR inhibitors for NSCLC patients, such as gefitinib and erlotinib, were some of the earliest fruits of personalized oncology. More efficacy, less side effects than conventional chemotherapy, these therapies provide treatment alternatives for the disease.
- **HER2-Targeted Therapies in Breast Cancer**: Another revolution came with trastuzumab (Herceptin), the monoclonal antibody directed against the HER2 receptor in breast cancer patients with overexpression of HER2. This therapy significantly increased survival in HER2-positive breast cancer patients.
- **BRAF Inhibitors in Melanoma**: By now, targeted therapy for BRAF mutation, such as vemurafenib, in melanoma has emerged as one of the important milestones in personalized oncology, dramatically improving outcomes in patients with BRAF-positive melanoma.

Next-generation sequencing (NGS) power during this historic period allowed more fine-grained genetic analysis of tumors such that tumor heterogeneity could be better understood and new therapeutic targets might be identified. NGS technologies made it possible to identify a broad array of mutations in genes that might drive cancer, allowing the application of more precise treatment constructs.[11,12]

4. The Rise of Immunotherapy (2010s–Present)

The advent of Immunotherapy (2010s-present): As the targeted therapy trend gathered momentum

immunotherapy stood as a game changer in cancer therapy. Basically, immunotherapy is ramping up one's immune system to fight the organ with cancer and personalized immunotherapy aims at finding out those biomarkers indicating the successful response to said therapies.

- **PD-1/PD-L1 Inhibitors**: The introduction of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, completely changed the game for cancers such as melanoma, non-small cell lung cancer, and renal cell carcinoma. Because these drugs did consume the PD-1/PD-L1 pathway, immune cells, at least some of them, might now recognize and attack the cancer cells more readily.
- **Biomarker-Driven Therapies**: Immunotherapy has become extremely individualized through the discovery of biomarkers such as PD-L1 expression, which predict which patients will benefit from these therapies. Tumor mutational burden (TMB) and microsatellite instability (MSI) will be used to help drive treatment decisions as well.

5. Integration of Liquid Biopsy and Molecular Profiling (2010s–Present)

An infusion of liquid biopsy and molecular profile (2010s-present): It further strengthened greatly the role of liquid biopsy-an application, namely, a non-invasive cancer-related genetic alteration detection from blood in enhancing personalized oncology. Reality monitoring via liquid biopsy includes tumor-, resistance mechanisms as well as the progression of a disease.

- **Monitoring Tumor Evolution**: Liquid biopsy enables genetic mutations in tumor evolution to be monitored by a clinician, which can shed light on new mutations as well as treatment resistance.
- **Personalized Treatment Adjustments**: Allows for personalized treatment changes based on specific alterations necessitating a change in therapy, while minimizing the need for invasive tumor biopsy.

Potentially providing a reference framework, molecular profiling has been active and is becoming more prevalent in its use as a motivation for treatment decisions. Advanced platforms have emerged that can detect a plethora of cancers and make such loci actionable. In consequence, several FDA-approved targeted therapies on specific mutations are coming up, thus entrenching more the genetic and molecular profiling in personalized oncology.[13,14,15]

Traditional Cancer Treatments vs. Personalized Cancer Therapies

1. Traditional Cancer Treatments:

- **Chemotherapy**: Traditionally, chemotherapy is the cornerstone of cancer treatment. It is the treatment given for rapidly cell-multiplying tissues and is nonselective for cancerous and healthy cells. Therefore, its side effects are often severe, such as fatigue, hair loss, and nausea.
- **Radiation**: Similar to chemotherapy, radiation therapy is targeted on cancerous tissues; however, it may damage surrounding healthy tissues which leads to delayed side effects.
- **Surgery**: Even though surgery works well for solid tumors, it doesn't work for most metastatic or inoperable cancers and also doesn't address molecular mechanisms by which the cancer actually grows.
- **Limitations**: Most of these therapies don't consider the genetic and molecular differences present between different individual patients' tumors, thus often accounting for all these differing responses. In some cases, tumors develop resistance to treatment, whereas side effects can be really debilitating.

2. Personalized Cancer Therapies

- **Targeted Therapies**: These are therapies that can induce 'point mutations' or 'amplifications' which specifically target the alteration in molecular signatures that drive cancer growth. An example of this is HER2-targeted therapies for breast cancers such as trastuzumab or EGFR inhibitors in non-small cell lung cancer, for example, erlotinib.
- **Immunotherapy**: Personalized to the use of checkpoint inhibitors (like pembrolizumab), such therapies are well defined to empower the host immune system to identify and destroy cancer cells. PD-L1 expression, among others, is an example of a biomarker useful in predicting likely benefiting patients from such treatments.
- **Gene Therapy**: Gene therapy usually undertakes correction or replacement of mutant genes resulting in cancer growth or encouraging cancer growth. Although it is at the trial stage, gene therapy appears to hold a lot of promise.
- **Limitations of Personalized Therapies**: Personalized therapies, that have a big promise, still have challenges. Among them are tumor heterogeneity (the tumor consists of different mutations within the same tumor), and high cost targeted therapies.[16,17,18]

ROLE OF GENETIC AND MOLECULAR PROFILING IN PERSONALIZING TREATMENT

The genetic and molecular profiling come right at the center as personalized oncology is concerned with creating a richly detailed picture of the genetic landscape of a patient's cancer. Profiling, in essence, consists of analyzing the DNA, RNA, and proteins within a tumor in order to find mutations, gene amplifications, fusions, or any other kinds of changes that can potentially be targeted by specific therapies.

Key components include

1. Genetic Sequencing: Technologies such as next-generation sequencing (NGS) allow for wide coverage of cancer-associated mutations, chromosomal rearrangements, and gene expression profiles, thus paving the way for possible navigation on targeted therapies.

2. Tumor Profiling: Analysis of tumor DNA, RNA, and Protein holds the potential to glean critical information about the molecular pathways of the tumor, helping identify therapeutic targets or resistance mechanisms.
3. Biomarker Identification: Among numerous markers include HER2 in breast cancer, EGFR in lung cancer, and BCR-ABL in chronic myelogenous leukemia (CML) to guide clinicians in selecting appropriate therapies and predicting drug responses.
4. Liquid Biopsy: This is an alternative, non-invasive method for conventional biopsy, evaluating the tumor-derived DNA or RNA that is found in blood or other fluids of the body. It thus allows for assessment of tumor progress and change in response to treatment in real time.[19,20]
Genetic and molecular profiling allows oncologists to:

- Identify mutations or gene alterations that might allow specific therapies to target.
- Predict the likely response of patients to treatment based on biomarkers.
- Monitor the progression of disease with serial profiling to account for adjustments to treatment.

Integration of Precision Medicine into Clinical Practice
It includes introducing precise personalized medicine into the regular routine of clinical practice by including genetic and molecular testing into the management of patients.
1. Routine Genetic Testing: Today so many of the cancer centers have developed routine genetic testing for the most common mutations to assist in treatment decisions. For example, BRCA mutations in breast cancer patients or mutations in the EGFR gene in lung cancer patients.
2. Multidisciplinary Approach: Applying personalized medicine requires close cooperation of oncologists, genetic counselors, molecular biologists, and pharmacists to establish a tailored treatment plan.
3. Clinical Trials: Development and design of clinical studies by personalized medicine provide targeted therapy based on specific genetic profiles. Those clinical studies would also help delineate efficacy evidence for personalized therapy and direct patients to advanced treatment.
4. Clinical Guidelines: The development of clinical guidelines incorporating genetic testing and personalized treatment strategies is imperative to allow patients to benefit from the most recent innovations in precision medicine.[21,22]

Benefits of Personalized Approaches in Improving Treatment Outcomes
1. Increased Efficacy: Personalized medicine greatly enhances the odds of achieving successful treatment outcome by choosing treatments that target the specific molecular drivers of a patient's cancer.
2. Reduced Side Effects: Compared to traditional chemotherapy and radiation therapy, more side effects are avoided from personalized therapy treatment designed to target cancer cells specifically and therefore straying away from damage to normal healthy cells.
3. Overcoming Resistance: Personalized medicine identify early the resistance mechanisms and proceed with treatment plans that to allow the patient to overcome the resistance or bypass it resulting to long term follow up results improvement.
4. Improved Survival Rates: Personalized medicine can lead to a considerable increase in survival rates, as well as improving the quality of life for cancer patients, because it provides more efficient therapies tailored for individual patients.
5. Better Prognostic Information: By molecular profiling, oncologists can now provide more reliable prognostic information for patients and enable them to make better-informed decisions concerning treatment choices and end-of-life practices.

Altogether, personalized medicine is a paradigm shift in cancer care, emphasizing the uniqueness of every cancer in every patient to provide intervention that is more precise, effective, and relationally personal. Although challenges continue to exist in this direction, the future of oncology lies in capitalizing on the all promise molecular and genetic information can offer in improving outcomes for cancer patients.[23,24]

FUNDAMENTALS OF GENETIC PROFILING IN CANCER

Genomic profiling is to examine the genome of cancer cells to find mutations or changes that account for cancer development and progression. This is important for understanding the behavior of specific cancers, which can then inform personalized treatment plans for achieving better outcomes. Here's a brief description of the most relevant parts of genetic profiling in cancer.

Genetic profiling examines a patient's tumor's DNA, RNA, and sometimes proteins to find genetic mutations, gene expressions, and molecular changes associated with that cancer. This profile may form the basis for conducting its treatments or choosing targeted therapies and predicting the cancer behavior or response to therapy.

Key Elements of Genetic Profiling

- **Gene Mutations**: A mutation to genes can give rise to stimulation of cancer-promoting signals or removal of genes that block cancer. Commonly used mutations are oncogenes (such as HER2 and EGFR) and tumor suppressor genes (such as p53 and BRCA1) that can be profile based on genetics.
- **Gene Expression**: Genetic profiling can shed some light on how active specific genes are concerning cancers. For instance, over-expression of one gene (i.e. HER2) may suggest that the cancer will respond favorably to any therapeutic attempts concentrating on that gene.

- **Chromosomal Alterations** Cancers are frequently associated with structural alterations of chromosomes that can be deletions, duplications, or rearrangements. All these changes can be captured by genetic profiling. An example of such a genetic alteration is the Philadelphia chromosome found in chronic myeloid leukemia conditions.
- **Tumor Mutational Burden (TMB)**: TMB is a measure of the number of mutations in a tumor DNA. Tumors higher in TMB are expected to respond to immunotherapy better, as such tumors are more likely to have their cells recognized and attacked by the immune system due to the higher number of mutations.
- **Microsatellite Instability (MSI)**: A condition of hypermutability genetic in which errors in DNA repair mechanisms lead to a high-frequency mutation: high MSI tumors are more likely to respond to immunotherapy.[25,26,27]

Techniques for Genetic Profiling

There are several different advanced technologies for performing genetic profiling in cancer. These include:

- **Next-Generation Sequencing (NGS)**: NGS tests are capable of analyzing many thousands of genes for all types of mutations, fusions, and other alterations usually for building a comprehensive genetic profile of tumoral tissue.
- **Polymerase Chain Reaction (PCR)**: PCR amplifies a particular region of DNA for identifying a mutation in a specific gene. Usually, PCR can amplify several mutations in targeted genes like EGFR or KRAS for lung and colorectal cancer.
- **Fluorescence In Situ Hybridization (FISH)**: FISH is a technique that can detect chromosomal rearrangements with regard to gene amplifications or gene translocations with the use of fluorescent probes which complement specific genetic sequences.
- **Chromosomal Microarray**: Detection of such chromosomal gains and losses is one technology that is helpful in identifying genetic changes associated with cancer.

Key Genetic Markers in Cancer Treatment

The field of genetics holds an important key toward identifying specific molecular targets that personalize them for particular cancer treatments. This enables mutations, alterations or expressions to certain genes to be identified and for an optimal treatment to be presented and supplied as per the patient's individual genetic profile of cancer.

EGFR (Epidermal Growth Factor Receptor)

EGFR gene mutation is found mostly in non-small cell lung cancers (NSCLC) and in some cancers of the head and neck. Mutations in EGFR give rise to uncontrolled cell division, leading targeted therapies like Erlotinib and Gefitinib to be used to block this pathway, thereby increasing treatment efficacy among EGFR-positive cancers.

HER2 (Human Epidermal Growth Factor Receptor 2)

HER2 over expression or amplification was identified in breast cancer, which is aggressive forms. HER2-positive breast cancers were treated with trastuzumab (Herceptin) monoclonal antibody that specifically targets and inhibits HER2, inhibiting growth of cancers and leading to improvement in patient outcome.

BRCA1 and BRCA2 (Breast Cancer Genes)

Mutations in genes BRCA1 and BRCA2 hugely increase chances of breast, ovarian, and other types of cancers. Patients with mutations in these two genes can benefit from PARP inhibitors: Olaparib or Rucaparib, which work by targeting cancer cells lacking DNA repair mechanisms, leading to cancer cell death.

KRAS (Kirsten Rat Sarcoma Virus)

KRAS mutations are found in a variety of tumor types, including pancreatic, colorectal, and lung cancers, and they propagate pathways that promote the growth of carcinoma cells. Until recently, KRAS mutations were regarded as input that could not be targeted by any therapy, but newer treatments, particularly sotorasib, specifically target certain mutated forms of KRAS, such as in patients with non-small cell lung cancer (NSCLC).

BRAF (B-Raf Proto-Oncogene)

BRAF mutations can most often be found in melanoma, for instance, colonic and thyroid cancers. The V600E mutation gives rise to an inability to contain cell divisions. Targeted therapies, that is to say, vemurafenib and dabrafenib have efficacy in circumventing such mutated BRAF protein that would normally evoke adverse outcomes in a patient with BRAF mutants.

MSI-H (Microsatellite Instability-High)

MSI is an inheritance pattern seen where change occurs in the length of microsatellites (short DNA repeat sequences) owing to defects in the DNA mismatch repair system. MSI-high cancers, such as some types of colorectal cancers, are associated with a greater likelihood of being treated successfully with immune checkpoint inhibitors such as pembrolizumab and nivolumab.

PD-L1 (Programmed Death-Ligand 1)

Determining PD-L1 expression in tumor and immune cells is a main feature in selecting patients for immune checkpoint inhibitors. High PD-L1 expression on neoplasm cells increases likelihood of response with immunotherapies, such as nivolumab and atezolizumab, which block the PD-1/PD-L1 pathway and stimulate anti-cancer immune activity.

TP53 (Tumor Protein p53)

TP53 mutations are frequently associated with cancers and progress in the malignant process and prognosis. Despite TP53 not being directly targetable in treatments, its mutation status serves as a considerable predictor of

tumor behavior and treatment strategy, such as chemotherapy versus immunotherapy based on tumor molecular profile.

ALK (Anaplastic Lymphoma Kinase)
ALK gene rearrangements occur in NSCLC and certain lymphomas. The targeted therapies crizotinib and alectinib act against the aberrant ALK protein and produce tumor shrinkages and improvements in prognosis in ALK-positive tumors.

PIK3CA (Phosphatidylinositol 3-Kinase Catalytic Subunit Alpha)
Mutations in PIK3CA can be identified in various cancers, including malignant tumors of the breast, colon, and endometrium. These mutations often activate the PI3K/Akt pathway, which is associated with cell survival, growth, and other characteristics normally associated with neoplastic transformation. An example of a PI3K inhibitor that is useful to address mutations in certain cancers and enhance therapeutic effectiveness is alpelisib.[28,29,30]

ROLE OF GENETIC PROFILING IN PERSONALIZED CANCER THERAPY

The rapid development of genetic profiling is resulting in personalized cancer therapies as the central axis transforming cancer diagnosis, therapy, and monitoring. By using the individual genetic make-up of a tumor, genetic profiling provides a thorough understanding of mutations, alterations, and the molecular pathways driving cancer. Information enables treatment strategies that can boost the efficacy of therapy, decrease side effects, and help identifying the most appropriate therapies depending on a given patient's cancer type and genetic profile.

1. Identification of Targetable Mutations
Genetic profiling is beneficial in identifying specific mutations in the genes that help in cancer progression. General alterations in oncogenes or tumor suppressor genes are linked with various kinds of tumors. For instance, there are mutations in EGFR gene from non-small cell lung cancers (NSCLC), BRAF V600E mutation in melanoma, and both can easily be identified through broad-based genetic profiling. These will then be treatable with targeted therapy, that is, using agents such as EGFR inhibitors (e.g., gefitinib, erlotinib) or BRAF inhibitors (e.g., vemurafenib), which are molecularly blocking the pathways fueling tumor growth. Thus, once targeting those mutations, personalized therapy works best to cure the cancer with minimal collateral damage to healthy tissues.

2. Predicting Response to Treatment
In terms of predictive ability, gene profiling could state how a person would respond to certain treatments. A tumor with a specific genetic mutation would be receptive to a targeted therapy, while others may be resistant. HER2-positive breast cancer is often treated with HER2 inhibitors (such as trastuzumab) when established by genetic profiling, and that brings better outcomes. In contrast, cancers with mutations that are related to drug metabolism or resistance mechanisms are either strongly or poorly antineoplastic programs. Clinicians could select the proper treatment by discovering these genetic aspects, powering down the wasteful usage of non-effective medicines, thus decreasing the risk of side effects.[31,32]

3. Monitoring Treatment Response and Resistance
Genetic profiling is an important diagnostic and therapeutic tool in cancer management but also permits monitoring over time of the tumor's response to therapy. The tumor evolves from the primary profiles of drug sensitivity during treatment by acquiring other mutations that could even lead to drug resistance. For example, though initially showing response to EGFR inhibitors, NSCLC tumors may escape through the development of a secondary mutation such as T790M. Regular genetic profiling of tumor samples, either by one-time or liquid biopsy, will eventually be used to detect such resistance mutations early and subsequently result in readjustments to treatment regimens, including second-line therapies or combination therapies.

4. Personalized Drug Selection
In personalized cancer therapy, genetic profiling leads to a choice of drugs that can be custom-built to the specific genetic alterations in the patient's tumor by not giving a "one-size-fits-all" approach that the traditional treatment provides using therapies more specific to the molecular characteristics of the cancer. For example, some immunotherapies target certain proteins, such as PD-1 or PD-L1, that the specific tumor over-expresses: their use only in cancers where these proteins reflect increased amounts. Likewise, some PARP inhibitors are given to those with BRCA mutations because of their sensitivity to agents that inhibit DNA repair mechanisms.

5. Assessing Prognosis and Risk
Genetic profiling serves as an important prognostic factor in cancer patients. There are certain mutations or variations in the genes that may result in aggressive behavior of cancer, while the opposite may show a positive prognosis for a patient. Besides this, BRCA1/2 mutations known for breast cancer are said to have a high risk of recurrence, but the mutations are likely to increase your chances of treating the disease with targeted methods like PARP inhibitors. This will enable them to set follow-up forms of care and monitor for relapses with more accurate prognosis from the information gained on these genetic factors.[33,34,35]

6. Customized Chemotherapy Regimens
Chemotherapy is the mainstay of cancer therapy; however, many such patients will not respond to it because of some mutations present in their genes that would determine sensitivity to drugs. Genomic profiling will help determine whether the tumor is sensitive or

resistant to the drug. For example, TP53 mutation assay in tumors could indicate whether certain drugs could be used against that cancer. It helps in optimization of chemotherapy, avoiding unnecessary treatments, and minimizing toxic side effects.

7. Early Detection and Prevention

Not only does genetic profiling come into play in the context of early cancer detection and prevention, it can also be used by patients who suffer from hereditary genetic mutations that predispose them to a particular risk of developing cancer (for instance, mutations in BRCA1/2 that occur in breast and ovarian cancers, or mutations related to Lynch syndrome in colon cancer) in order to take more frequent monitoring or preventive interventions. Genetic profiling allows the implementation of strategies to reduce the chances of cancer development or catches it at an early, more manageable stage by detecting predisposition early.

8. Liquid Biopsy for Non-Invasive Monitoring

Liquid biopsy is considered one of the most notable advances in genetic profiling because it makes it possible to analyze circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) from a sample of blood. This simple procedure is a non-invasive way of monitoring how well a cancer is doing, to see if it has gone into relapse too early on from treatment, and to take a measure of treatment efficiency. Liquid biopsy gives a means to follow genetic alteration and mutations over time without requiring repeated biopsies because it analyzes ctDNA, which reflects genetic changes in the tumor. Liquid biopsy will be applicable mostly for those patients who can't go for traditional biopsy because of certain tumor locations or other reasons.

BENEFITS OF GENETIC PROFILING IN CANCER

- **Tailored Treatment Plans**: Genetic profiling identifies the specific mutations in a cancer, thereby tailoring the appropriate treatment to the individual so that the odds of a successful outcome are increased while the unnecessary side effects are reduced.
- **Early Detection of Resistance**: Profiling would be able to early identify potential resistance mechanisms; therefore treatment could be adapted in time before it proves ineffective.
- **Better Prognosis and Treatment Decisions**: A deeper understanding of the genetic make-up of the tumor will allow a physician to better predict how aggressive the cancer is and thus allow for more accurate screening for the most efficient treatment.
- **Reduced Side Effects**: Patients are less likely to experience severe side effects that are usually associated with conventional treatments like chemotherapy, as such treatments are directed much more accurately against cancer cells.[36,37]

CHALLENGES IN GENETIC PROFILING

- **Tumor Heterogeneity**: Tumors may have multiple genetic alterations and different parts of a tumor may show different mutation patterns. Within the tumor, heterogeneity may restrict selection of appropriate therapy which could treat all cancer cells.
- **Cost and Accessibility**: Genetic profiling could be expensive and cannot be made available in all the healthcare setups requiring the use of infrastructure especially in low resources regions.
- **Ethical and Privacy Concerns**: Genetic information collection gives much rise to privacy issues, data security and the way data is utilized in clinical practice.

FUTURE DIRECTIONS IN PERSONALIZED CANCER MEDICINE

1. Advancements in Liquid Biopsy Technology

Liquid biopsy technologies will enter the "mainstream" of future personalized cancer medicine. The blood sample analysis technologies would enable genetic alterations and mutations in cancer cells to be identified. Ultimately, this approach will revolutionize cancer diagnosis, treatment, and early diagnosis of cancers before developing relapse. As technologies related to liquid biopsies improve, they will be able to replace invasive biopsy in many cases with a better opportunity of access and frequency for monitoring cancer progression.

2. Expansion of Targeted Therapies

With the deepening of knowledge in cancer genomics, more and more targeted therapies are going to emerge for the treatment of cancers with specific genetic mutations. Many cancers are still without an effective targeted therapy. Still, the development of molecularly targeted drugs is an undersupported field that one day may be able to produce therapies for mutations that have not been treatable before. In a few years, it is expected that drug pipelines will be integrated to a much greater extent in targeting several genetic alterations across a broader spectrum of cancers.

3. Integration of Artificial Intelligence (AI) and Machine Learning (ML)

The combination of AI and ML with genetic profiling will bolster the effort for personalized cancer therapy significantly. AI is likely to help in the quick and accurate analysis of such complex genomic data and finding patterns and potential therapeutic targets that may not be obvious through traditional methods. AI-driven algorithms may also be used to predict how tumors will respond to specific therapies, enabling clinicians to make more informed decisions in real-time.

4. Comprehensive Tumor Profiling

Complete tumor profile has a promising future in personalized cancer medicine. It is going beyond genetic mutation and dealing with the whole spectrum of molecular alteration. It includes a test on the tumor

genetic, epigenetic, proteomic, and transcriptomic profiles to add a more complete picture of its biology. Using that multi-dimensional data, it should be possible for clinicians to customize and improve their treatment regimens to optimize outcomes for more complex, heterogeneous tumors.

5. Personalized Immunotherapy

Immunotherapy is, indeed, a breakthrough treatment for cancer, but not for all patients. In the future, genetic profiling will have an even greater role in determining the patient population that is most likely to respond to immunotherapy. Such treatments will be personalized on the basis of predicting responsiveness of the immune system to such molecular biomarkers as PD-L1 expression or mutational burden, allowing treatment with checkpoint inhibitors and CAR T-cell therapy to enhance the body's immune response to cancer.[38,39]

6. Enhanced Early Detection of Cancer

Genetic profiling will increasingly serve new roles in early detection programs by defining cancer at an ever earlier and more treatable stage. Newer genetic tests can reveal the existence of blood and other bodily fluids of cancer-associated mutations before symptoms appear. With earlier detection of cancer, paired with personalized treatment plans based on genetic data, survival rates can be dramatically improved while the need for more invasive treatments is decreased.

7. Overcoming Resistance to Targeted Therapies

Resistance development is one of the major researched hurdles in cancer treatment. Tumors arise and develop some new mutations which resist or counteract the first-targeted treatment. Personalized medicine will shift toward investigating early resistance mechanisms by continuous genetic profiling and providing this information to oncologists for creating strategies to overcome those mechanisms through approaches such as combination therapy or development of second-generation targeted drugs capable of dealing with resistant cancer cells.

8. Patient-Centered Genetic Databases and Networks

Large-scale patient-specific genetic databases are more likely to enable personalized medicine-generic diagnosis-treatment modalities. With such databases, genetic information from diverse population groups may be collected and analyzed to discover previously rare mutations, understand better the more efficient treatment of inadequately represented populations, as well as the establishment of networks of cooperation among hospitals, research centers, and pharmaceutical companies to further support data pooling for faster new therapy development.

9. Pharmacogenomics Integration in Treatment Planning

With advances in pharmacogenomics-the science of how genes affect drug response-medicine will take one more step towards personalized cancer treatment as clinicians will be able to predict which drug is likely to answer best for each individual patient according to his or her genetic makeup. So, even the trial and errorapproach would be reduced to a point, for cancer treatment, improving drug efficacy and experiencing fewer adverse effects. This will be part and parcel of cancer therapy as pharmacogenomics-based personalized medication regimens.

10. Expanding Genetic Testing to All Cancer Patients

Broadly in the future, genetic testing is going to be administratively implemented for all cancer patients, notwithstanding types of cancer they have an unusual feature. It would allow comprehensive genetic profiling to reveal actionable mutations even in rare cancers for personalized treatment options for all cancers. Routine genetic testing would lead to upfront identification of the best action to take in a more significant number of patients at the outset of treatment for a better outcome.[40]

CONCLUSION

Personalized medicine, based on genetic profiling, represents a significant advancement in cancer treatment, offering a more precise, targeted approach that improves patient outcomes. By identifying specific genetic mutations and molecular markers, genetic profiling enables the selection of tailored therapies, optimizing efficacy and minimizing adverse effects. The integration of technologies like next-generation sequencing, liquid biopsy, and bioinformatics has revolutionized the ability to understand tumor biology and customize treatments. However, challenges such as high costs, limited access, and the complexity of genetic data interpretation remain obstacles to broader implementation. Despite these barriers, the future of personalized cancer treatment looks promising, with ongoing advancements in multi-omics approaches, artificial intelligence, and improved accessibility. As these technologies continue to evolve, personalized medicine is expected to play an even more central role in cancer therapy, offering a path toward better outcomes, higher survival rates, and improved quality of life for patients.

REFERENCES

1. 1. Piña-Sánchez P, Chávez-González A, Ruiz-Tachiquín M, Vadillo E, Monroy-García A, Montesinos JJ, Grajales R, Gutiérrez de la Barrera M, Mayani H. Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective. Cancer Control, 2021 Jan-Dec; 28: 10732748211038735.
2. Hickey R, Vouche M, Sze DY, et al. Cancer concepts and principles: Primer for the interventional oncologist-Part II. J Vasc Intervent Radiol, 2013; 24(8): 1167-1188.
3. Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol, 2018 Jun; 15(6): 353-365.

4. Meyerson M, Gabriel S & Getz G Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet, 2010; 11: 685–696.
5. Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci), 2018 Sep-Dec; 6(3-4): 79-100.
6. Personalized Medicine Coalition. The personalized medicine report. Opportunity, challenges, and the future (2017), http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/The_PM_Report.pdf
7. Kalia M. Personalized oncology: recent advances and future challenges. Metabolism, 2013 Jan; 62 Suppl 1: S11-4.
8. Maciejko L, Smalley M & Goldman A Cancer immunotherapy and personalized medicine: Emerging technologies and biomarker-based approaches. J. Mol. Biomark. Diagn, 2017; 8.
9. Durmaz AA, Karaca E, Demkow U, Toruner G, Schoumans J, Cogulu O. Evolution of genetic techniques: past, present, and beyond. Biomed Res Int, 2015; 2015: 461524.
10. Gall J. G., Pardue M. L. Formation and detection of RNA-DNA hybrid molecules in cytological preparations. Proceedings of the National Academy of Sciences of the United States of America, 1969; 63(2): 378–383.
11. Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM. Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging, 2017 Aug; 44(Suppl 1): 41-54
12. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med, 2007; 13(12): 527–534.
13. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol, 2020 Aug; 17(8): 807-821.
14. Bonanno L, Dal Maso A, Pavan A, et al. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? Br J Cancer, 2022; 127: 383-93.
15. Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med, 2019; 25: 1928-37.
16. Liu, B., Zhou, H., Tan, L. *et al.* Exploring treatment options in cancer: tumor treatment strategies. *Sig Transduct Target Ther* **9**, 175 (2024). Liu, B., Zhou, H., Tan, L. *et al.* Exploring treatment options in cancer: tumor treatment strategies. *Sig Transduct Target Ther*, 2024; **9**: 175.
17. Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol, 2020 Apr; 17(4): 233-250.
18. Das SK, Menezes ME, Bhatia S, Wang XY, Emdad L, Sarkar D, Fisher PB. Gene Therapies for Cancer: Strategies, Challenges and Successes. J Cell Physiol, 2015 Feb; 230(2): 259-71.
19. Riedl JM, Moik F, Esterl T, Kostmann SM, Gerger A, Jost PJ. Molecular diagnostics tailoring personalized cancer therapy-an oncologist's view. Virchows Arch, 2024 Feb; 484(2): 169-179.
20. Luchini C, Lawlor RT, Milella M, Scarpa A. Molecular tumor boards in clinical practice. Trends Cancer, 2020; 6(9): 738–744.
21. Satam H, Joshi K, Mangrolia U, Waghoo S, Zaidi G, Rawool S, Thakare RP, Banday S, Mishra AK, Das G, Malonia SK. Next-Generation Sequencing Technology: Current Trends and Advancements. Biology (Basel), 2023 Jul 13; 12(7): 997.
22. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, Zhao J, Snowdon JL. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci, 2021 Jan; 14(1): 86-93.
23. Babu, B. K. (2024). Personalized Medicine and Advancements in Pharmacology: Shaping the Future of Healthcare. *International Journal of Pharmaceutical Investigation*, *14*(2): 338–342.
24. Chiauzzi E, Rodarte C, DasMahapatra P. Patient-centered activity monitoring in the self-management of chronic health conditions. *BMC Med*, 2015; 13(1): 77.
25. Zhang J, Späth SS, Marjani SL, Zhang W, Pan X. Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. Precis Clin Med, 2018 Jun; 1(1): 29-48.
26. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature, 2012; 487: 330–7.
27. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013; 499: 214–8.
28. Guglielmini PF, Rossi M, Grosso F, et al. Double KRAS and BRAF mutations in colorectal cancer in a single oncologic department series. J Clin Oncol, 2013; 31.
29. Mardis ER. The Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to Clinic. Cold Spring Harb Perspect Med, 2019 Sep 3; 9(9): a036269.
30. Quraish RU, Hirahata T, Quraish AU, Ul Quraish S. An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies. Cancer Inform, 2023 Feb 1; 22: 11769351221150772.

31. Singer J, Brauneck E, Zwickl-Traxler E, Pecherstorfer M. Evaluation of personalized cancer therapies based on comprehensive genomic profiling in a middle-sized oncologic center in Austria, the University Clinic Krems. Transl Oncol, 2021 May; 14(5): 101021.
32. Rubini D, Gagliardi F, Menditti VS, D'Ambrosio L, Gallo P, D'Onofrio I, Pisani AR, Sardaro A, Rubini G, Cappabianca S, Nardone V, Reginelli A. Genetic profiling in radiotherapy: a comprehensive review. Front Oncol, 2024 Jul 26; 14: 1337815.
33. Malone, E.R., Oliva, M., Sabatini, P.J.B. *et al.* Molecular profiling for precision cancer therapies. *Genome Med*, 2020; **12**: 8.
34. Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, Gelb BD, Ginsburg GS, Hassenstab J, Ho CM, Mobley WC, Nolan GP, Rosen ST, Tan P, Yen Y, Zarrinpar A. Enabling Technologies for Personalized and Precision Medicine. Trends Biotechnol, 2020 May; 38(5): 497-518.
35. Chen Z, Sun T, Yang Z, Zheng Y, Yu R, Wu X, Yan J, Shao YW, Shao X, Cao W, Wang X. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Mol Genet Genomic Med, 2020 Feb; 8(2): e1079.
36. Ultimescu F, Hudita A, Popa DE, Olinca M, Muresean HA, Ceausu M, Stanciu DI, Ginghina O, Galateanu B. Impact of Molecular Profiling on Therapy Management in Breast Cancer. *Journal of Clinical Medicine*, 2024; 13(17): 4995.
37. Lassen, U. N., Makaroff, L. E., Stenzinger, A., Italiano, A., Vassal, G., Garcia-Foncillas, J., & Avouac, B. (2021). Precision Oncology: a Clinical and Patient Perspective. *Future Oncology*, *17*(30): 3995–4009.
38. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta, 2010 Jan; 1805(1): 105-17.
39. Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer, 2015 Jul 15; 137(2): 262-6.
40. Masucci M, Karlsson C, Blomqvist L, Ernberg I. Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine. *Journal of Personalized Medicine*, 2024; 14(6): 561.